Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 613

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 613
---
 ​ | ​ | ​ | ​ | ​    | ​ |       ​ | ​ | ​ | ​ | ​      | ​ |      ​ | ​ | ​ | ​ | ​       | ​ | ​        | ​ | ​ |
| Interest income            | ​ | ​ | ​                       | ​ |   1,318 | ​ | ​ | ​ | ​    | ​ |     654 | ​ | ​ | ​ | ​      | ​ |    664 | ​ | ​ | ​ | ​       | ​ | 101.5%   | ​ | ​ |
| Interest expense           | ​ | ​ | ​                       | ​ |       — | ​ | ​ | ​ | ​    | ​ |      -2 | ​ | ​ | ​ | ​      | ​ |      2 | ​ | ​ | ​ | ​       | ​ | (100.0)% | ​ | ​ |
| Total other income, net    | ​ | ​ | ​                       | ​ |   1,318 | ​ | ​ | ​ | ​    | ​ |     652 | ​ | ​ | ​ | ​      | ​ |    666 | ​ | ​ | ​ | ​       | ​ | 102.1%   | ​ | ​ |
| Net loss                   | ​ | ​ | ​                       | $ | -17,347 | ​ | ​ | ​ | ​    | $ | -20,541 | ​ | ​ | ​ | ​      | $ |  3,194 | ​ | ​ | ​ | ​       | ​ | (15.5)%  | ​ | ​ |

Research and Development Expenses Research and development expenses for the years ended December 31, 2023 and 2022 were comprised of the following (in thousands, except percentages):

| ​                                                    
 ​                                                    | ​ 
 ​ | ​ 
 ​ | Year Ended December 31, 
 2023                    |   |        |   | ​ | ​ | 2022 |   |        |   | ​ 
 ​ | ​ 
 ​ | Change 
 Amount |   |        |   | ​ | ​ | Percent |   |         |   | ​ 
 ​ |
|:-----------------------------------------------------|:--|:--|:------------------------|:--|-------:|:--|:--|:--|:-----|:--|-------:|:--|:--|:--|:-------|:--|-------:|:--